

AMMF - THE CHOLANGIOCARCINOMA CHARITY

England & Wales · Charity number 1198095

Details

Status Registered

Legal form CIO

Registered 2022-03-01

Register [View on the Charity Commission register](#)

Contact

Address Enterprise House
Bassingbourn Road
Stansted
Essex
CM24 1QW

Phone 01279661479

Email info@ammf.org.uk

Website <https://ammf.org.uk/>

Activities

Objects: THE OBJECTS OF THE CIO ARE, FOR THE PUBLIC BENEFIT, THE ADVANCEMENT OF HEALTH, INCLUDING BY RAISING THE AWARENESS AND UNDERSTANDING OF CHOLANGIOCARCINOMA (BILE DUCT CANCER) AND RELATED CANCERS AND CONDITIONS INCLUDING THROUGH THE PROMOTION OF RESEARCH INTO CAUSES, TREATMENTS AND CURES; AND DISSEMINATION OF INFORMATION TO PATIENTS, CARERS AND HEALTH CARE PROFESSIONALS

Activities: AMMF operates across the UK:1. Funding research into methods of earlier diagnosis, effective treatments, causes & cures for CCA2. Providing support to those diagnosed with CCA and their loved ones, through a website, dissemination of information, and patient support 3. Raising awareness regarding CCA via the annual AMMF CCA Conference, and participating with other organisations & initiatives

Classification

- **How:** Makes Grants To Organisations, Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-01-31	£1,045,821	£821,432	£1,259,784	4
2024-01-31	£928,753	£878,196	£1,016,427	4
2023-01-31	£1,039,648	£700,481	£965,870	3

Trustees

Name	Role	Appointed
Noel Corrigan FORS	Chair	2022-03-01
Gillian Corrigan RN		2022-03-01
Harold Corrigan		2022-03-01
TOM MOREMENT		2022-03-01

AMMF - THE CHOLANGIOMYOCARCINOMA CHARITY

England & Wales - Charity number 1198095

Accounts

Charity registration number: 1198095
Company registration number: CEO28473

AMMF - The Cholangiocarcinoma Charity

(A Charitable Incorporated Organisation)

Annual Report and Financial Statements

for the Year Ended 31 January 2025

Edmund Carr LLP
Chartered Accountants & Statutory Auditor
146 New London Road
Chelmsford
Essex
CM2 0AW

AMMF - The Cholangiocarcinoma Charity

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 13
Statement of Trustees' Responsibilities	14
Independent Auditor's Report	15 to 19
Statement of Financial Activities	20
Balance Sheet	21
Statement of Cash Flows	22
Notes to the Financial Statements	23 to 33

AMMF - The Cholangiocarcinoma Charity

Reference and Administrative Details

Chairman	Mr Noel Corrigan
Trustees	Mrs Gillian Corrigan Mr Harold Corrigan Mr Tom Morement
Senior Management / Leadership Team	Mrs Helen Morement, CEO
Registered Office	Enterprise House Bassingbourn Road Stansted Essex CM24 1QW The charity is incorporated in England and Wales.
Charity Registration Number	1198095
Company Registration Number	CEO28473
Auditor	Edmund Carr LLP Chartered Accountants & Statutory Auditor 146 New London Road Chelmsford Essex CM2 0AW

**AMMF – THE CHOLANGIOCARCINOMA CHARITY
(REGISTERED NO: 1198095)**

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2025**

NOTE FROM THE TRUSTEES:

AMMF – The Cholangiocarcinoma Charity was registered with the Charity Commission as a Charitable Incorporated Organisation (CIO) during the year 2022. The CIO registered number with the Charity Commission is 1198095.

The charity was originally registered in 2002 under the name, The Alan Morement Memorial Fund (working title, AMMF) and was an unincorporated charity with the registration number 1091915.

However, because of the continuing growth of the charity, AMMF's trustees decided that it should transition as a legal entity from unincorporated registered charity status to that of a Charitable Incorporated Organisation (CIO). This involved lengthy work with the Charity Commission, and the new CIO status was approved on 01 June, 2022. At that point the work and all assets of the original charity passed to the new CIO charity.

The original charity and its registered number 1091915 will always remain in existence, with all records submitted to the Charity Commission still available on the Commission's website, but this entity will now remain in the background.

The new CIO is officially known as: AMMF – The Cholangiocarcinoma Charity, with the registered number: 1198095.

AMMF 's aims and objectives remain unchanged and the charity's work has continued seamlessly and without interruption since the inception of the CIO on 01 June 2022.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

The trustees present their report with the financial statements of the charity for the year ended 31 January 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities:

Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

AMMF's MISSION

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

AMMF's VISION

A world where people can live their lives free of cholangiocarcinoma (CCA) as a life-threatening disease.

AMMF – the Cholangiocarcinoma Charity is the only charity in the UK solely dedicated to cholangiocarcinoma (bile duct cancer). AMMF works nationally throughout the UK, as well as in Europe, and collaborates globally.

AMMF is wholly committed nationally and internationally to tackling the devastating primary liver cancer, cholangiocarcinoma (CCA) on all fronts and, ultimately, to help find a cure, through:

- **Support** - Providing information to individuals or groups to support a patient or loved one along their journey
- **Empowerment** – Empowering patients and their loved ones to advocate for themselves, seek better care, new treatment options and second opinions
- **Access** – Advocating for patients to ensure they have access to the latest treatment options and a minimum standard of care appropriate to them
- **Awareness** – Raising awareness of cholangiocarcinoma to support earlier diagnosis, fair and equal access to treatments, including new treatment approaches
- **Research** – Encouraging and supporting continued research into causes, diagnostics, and new treatment options for those with cholangiocarcinoma
- **Policy** – Working towards ensuring health care policies reflect the needs of those with cholangiocarcinoma

AMMF- The Cholangiocarcinoma Charity

Trustees' Report

Cholangiocarcinoma is under-represented and under-funded across all areas, including policy, services, and research. It is a poorly understood and under researched disease which is increasing in incidence not only in the UK but throughout the world. Lack of awareness and the difficulties of achieving clear and accurate diagnosis, mean that most are at an advanced stage and inoperable at time of their diagnosis.

Whilst surgery remains the only potentially curative treatment, there is now chemotherapy, targeted therapies and immunotherapy, and a growing number of clinical trials, in particular those investigating further targeted therapies and immunotherapies. However, a diagnosis of inoperable cholangiocarcinoma remains invariably fatal, and this is a situation that has not changed in decades. AMMF is committed to working to change this scenario, nationally and internationally.

Resolute in bringing about improvement for the cholangiocarcinoma patient, AMMF continues to work closely with patients and their carers, clinicians, healthcare professionals, researchers, and policy makers, as well as actively collaborating globally.

During the year 2024, the charity continued its advocacy work, especially in helping those with cholangiocarcinoma to navigate their way to continue essential treatments wherever possible.

Raising Awareness

The Rethink Liver Cancer Campaign

The aim of AMMF's 'Rethink Liver Cancer' campaign is to broaden the focus of liver cancer from being exclusively hepatocellular carcinoma (HCC) to highlight that cholangiocarcinoma (CCA) is also a primary liver cancer, and to raise awareness and influence health policy for better recognition, earlier diagnosis, and equitable treatment access.

'Soft launched' in October 2023 (Liver Cancer Awareness Month), The Rethink Liver Cancer Campaign, was formally launched on 20 February 2024 with a White Paper¹ based on the outcomes and the publications from AMMF's CCA data work, at an afternoon tea reception in The Terrace Pavillion at the House of Commons, Westminster.

AMMF's Westminster Reception - February 2024

Elliot Colburn MP, Chair of the All Party Parliamentary Group on Cancer, hosted the event and met and spoke with many of the guests. Noel Corrigan, Chair of AMMF's Trustees, introduced the formal part of the afternoon, Elliot Colburn gave an introductory talk, and AMMF's new video² showcasing the findings of the CCA data project was premiered. Helen Morement, AMMF's CEO, and Professor Shahid Khan of Imperial College London, then spoke about what led to the CCA data project, the results and the asks we now have for those who can change policy and improve the situation for all those with CCA.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

Amongst the attendees were a number of health care professionals with an interest in CCA, MPs and government health officials, NHS policy makers, patients and carers, and members of the press.

AMMF's Westminster reception resulted in press coverage of the event and the White Paper in some 140 different media outlets, nationally and internationally.

¹ <https://ammf.org.uk/rethink-liver-cancer-white-paper/>

² <https://www.youtube.com/watch?v=8C2nlz3-bc8&t=25s>

AMMF's Hybrid European Cholangiocarcinoma Conference - May 2024

AMMF's European Cholangiocarcinoma Conference 2024 was a three-day hybrid event showcasing groundbreaking research, innovative treatments, and the collaborative spirit of the cholangiocarcinoma (CCA) community.

The charity was delighted to welcome two internationally renowned specialists at the forefront of the CCA world, Professor Shahid Khan and Professor Chiara Braconi, as co-chairs of the 2024 conference. They expertly hosted a faculty of 45 international speakers and managed some challenging Q & A sessions, all exploring the conference theme – Accelerating Progress.

As in previous years, the conference brought together a diverse audience, including healthcare professionals (HCPs), researchers, medical students, patient organisations, patients, carers and patient advocates. This mix provided a unique platform for exchanging knowledge and perspectives, enhancing the understanding and management of CCA.

Impactful personal perspectives were shared by four CCA patients. Their powerful individual stories highlighted real-world challenges including the crucial need for specialist knowledge, early diagnosis, and comprehensive support systems.

AMMF's conference was endorsed by the [British Society for the Study of the Liver](#), and was a CPD accredited event, worth 22.5 hours CPD (Continuing Professional Development).

The full programme and all conference presentations from the three days were recorded and remain available to view via AMMF's website. See: <https://ammf.org.uk/ammf-conference-2024/>

AMMF Clinical Nurse Specialist Advisory Board – May 2024

On 08 May 2024, during AMMF's CCA conference, a workshop for Clinical Nurse Specialists (CNS) was held. Following this, at the nurses' request, an AMMF CNS Advisory Board has been set up. CNS Advisory Board Terms of Reference were prepared, circulated and approved, and a virtual meeting of the board will be scheduled for early in 2025.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

Faces of Cholangiocarcinoma – December 2024

The 'Faces of Cholangiocarcinoma' initiative was part of the next stage of the Rethink Liver Cancer campaign, which it is planned will run throughout 2025. To promote the ask for a 'Fairer Deal, Faster' for all those with cholangiocarcinoma, a photo shoot was arranged with the celebrity photographer, Rankin (Rankin waived his fee for the day, although the charity had to pay for the studio and ancillary personnel). Eight people with cholangiocarcinoma were photographed, including the designer Dame Zandra Rhodes, Katie Nichol (author and royal commentator), Charlie Shrager (model), and others well known to AMMF - Ilona Smith, Andrea Sheardown, Andy Clay, Judith Neptial, Benjamin Carey.

As part of this venture, a 'behind the scenes' video was created, which will be launched at the start of February 2025, Cholangiocarcinoma Awareness Month:

<https://www.youtube.com/watch?v=vDZ7mrkl86U>

And a new campaign video, "Rethink Liver Cancer – for a Fairer Deal Faster" for 2025 has been created, using interviews and film captured during the day at Rankin's studio:

<https://www.youtube.com/watch?v=9loCFcubudI>

Global Cholangiocarcinoma Alliance

The Global Cholangiocarcinoma Alliance (GCA) was established at AMMF's international workshop held in London in 2018. The aim of the Alliance is to provide a united voice through international collaboration, raise the global awareness of CCA, and to improve the education of both healthcare professionals and patients.

Since the GCA's inception in 2018, AMMF has acted as the not-for-profit partner in this venture, and AMMF's CEO Helen Morement is a co-chair on the international steering committee.

During 2024 the role of secretariat of the GCA, and the organisation of the annual World Cholangiocarcinoma Day in February, Cholangiocarcinoma Awareness Month, passed from the healthcare communications agency AXON to Colab Health who will now also manage the bespoke website and social media accounts.

Public Benefit

In forming the charity's objectives and planning the activities, the trustees have considered the Charity Commission's guidance in respect of public benefit.

ACHIEVEMENT AND PERFORMANCE

AMMF's Research Awards

AMMF- The Cholangiocarcinoma Charity Trustees' Report

AMMF remains committed to supporting research into cholangiocarcinoma. In 2024, based on the advice of AMMF's Scientific Advisory Board awards were offered and accepted by the following to support their research into cholangiocarcinoma:

University of Birmingham (Mr Kayani Kayani) – AMMF Ref: 2024/224

“Stable functional induced tregs: A novel means of immunosuppression for patients transplanted for cholangiocarcinoma in the era of transplant oncology”

Award: £99,557.81 (to be given in one instalment)

University College London Hospital (Dr Uma Mukherjee) – AMMF Ref: 2024/225

“Identifying and predicting resistance mutations in intrahepatic cholangiocarcinoma (iCCA)”

Award: £17,331.73 (to be given in two instalments)

Imperial College London (Prof Shahid Khan) – AMMF Ref: 2024/226

“Multiplexed detection of cell-free DNA, microRNA, and protein biomarkers to diagnose Cholangiocarcinoma and Hepatocellular Carcinoma using a novel nanopore-based sensing technology”

Award: £45,000.00 (to be given in two instalments)

During 2024 the following payments were made re existing awards:

University of Nottingham - AMMF Ref: 2022/214

An award totalling £24,250.00 was agreed to fund consumables in the work of Professor Kevin Gaston, Professor Sheela Jayaraman and Dr Isioma Egbuniwe on, “Ultra high-resolution mapping of spatial patterns of gene and protein expression in cholangiocarcinoma and the cholangiocarcinoma tumour microenvironment”.

The following payments (totalling £24,010.05) were made in respect of invoices received, for consumables used:

£5,472.00 was paid on 07.03.2024

£2,226.67 was paid on 29.05.2024

£2,226.67 was paid on 14.06.2024

£14,084.71 was paid on 23.12.2024

University of Glasgow – AMMF ref: 2023/218

£49,732.00 was paid on 18.03.24 representing the first instalment of the award of £99,464.00 agreed to fund the work of Professor Chiara Braconi and Dr Jen Morton in, “Identifying therapeutic opportunities for Biliary Cancers by investigating the role of Monocytes in drug response”.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

Imperial College London – AMMF Ref: 2024/226

£22,500.00 was paid on 23.12.24 representing the first instalment of the award of £24,000.00 agreed to fund the work of Professor Shahid Khan in, “Multiplexed detection of cell-free DNA, microRNA, and protein biomarkers to diagnose Cholangiocarcinoma and Hepatocellular Carcinoma using a novel nanopore-based sensing technology”.

AMMF's External Activities

The charity is recognized widely, nationally and internationally, amongst both the general public and within medical circles, for its work in the field of cholangiocarcinoma, and is frequently invited to become part of study groups and advisory boards, for example, the working group for Liver Transplantation for Cholangiocarcinoma, and the executive committee of Cholangiocarcinoma-UK.

AMMF is also a member of the European Network for the Study of Cholangiocarcinoma (ENS-CCA), an association of research groups from across Europe and beyond, actively working on basic, translational, and clinical research into cholangiocarcinoma, and AMMF's CEO is chair of the ENS-CCA Patient Advocacy Committee.

AMMF continues to be an active member of Cancer52, the alliance of rare and less common cancer organisations in the UK. AMMF's CEO, Helen Morement was appointed a board director/trustee of Cancer52 in 2014, and has continued in that role since then. She also acted as interim co-chair during 2023 and part of 2024 (with fellow Cancer52 board member, Rebecca Porta, CEO of The Urology Foundation) until the new Chair of Trustees was appointed. Through membership of Cancer52, AMMF is enabled to have a presence and a voice within every national cancer initiative and AMMF's trustees see this as providing an important opportunity to work more closely with this influential organisation, and in identifying priority challenges and opportunities for all those in the rare and less common cancers community.

BSG (British Society for Gastroenterology) Guidelines for the Diagnosis and Management of Cholangiocarcinoma

Led by Professor Shahid Khan, Imperial College London, and originally published in 2023, the guidelines which had been prepared by a multidisciplinary writing committee of UK experts from various specialties involved in the diagnosis and management of CCA, including AMMF's CEO, were updated during 2024 to include information on molecular profiling, targeted therapies, and the follow-up protocol after surgical resection for cholangiocarcinoma.

AMMF's CEO, Helen Morement, also had discussions with David Fitzgerald, Director – Policy and Strategy, NHS Cancer Programme, NHS England, who agreed that the guidelines, along with a data analysis of the various CCA therapies given, cancer alliance by cancer alliance (extracted from AMMF's published data work), should be circulated to all cancer alliances in England. This was done in October 2024.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

For more information and the BSG guidelines, see: <https://ammf.org.uk/guidelines-for-the-diagnosis-and-management-of-cholangiocarcinoma/>

HPB Pathway to Diagnosis

During the year, AMMF's CEO worked with Peter Hawkins, Programme Manager for Faster Diagnosis, NHS Cancer Programme, NHS England, on the HPB (Hepatobiliary) Cancers Diagnostic Pathways document. This document is to be used by all cancer alliances, their respective NHS trusts and other stakeholders. See: <https://www.england.nhs.uk/publication/implementing-a-timed-hpb-cancer-diagnostic-pathway-pancreatic-liver-bile-duct-and-gall-bladder/>

New therapy appraisals:

NICE (National Institute for Care and Excellence) and SMC (Scottish Medicines Consortium)

During 2024, AMMF was invited to submit written and oral statements in support of new therapy appraisals by NICE and the SMC. Following submissions and full appraisals, the following new therapies for cholangiocarcinoma were approved during 2024:

By NICE:

- Futibatinib (Lytgobi): for those with a previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement.

By the SMC:

- Ivosidenib (Tibsovo): a 2nd line treatment for those with an IDH1 mutation.

External events

As the charity continues to expand its work throughout the UK and into Europe, during the year AMMF's CEO received a number of invitations to speak about cholangiocarcinoma and the work of the charity at national and international conferences during the year and presented at the following:

- 02 February - CCA-UK (Cholangiocarcinoma-UK): Annual Meeting, London.
- 08 February - ILCM (International Liver Cancer Movement) CCA Webinar (virtual).
- 15 February - APiC (Italian CCA Patients Association) Annual meeting (virtual).
- 26 -27 April - ILCA (International Liver Cancer Association) Congress, Madrid, Spain.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

- 01-02 July - ENS-CCA (European Network for the Study of Cholangiocarcinoma) Conference, Krakow, Poland.
- 19 July - NHS England – Circulating DNA (CtDNA) and Genomics Conference, London.
- 13 – 17 September, ESMO (European Society of Medical Oncology) Annual Congress and ATUVIBI (Spanish CCA advocacy group) event, Barcelona, Spain.
- 30 September - University of Glasgow & University of Edinburgh, NHS Scotland – Scottish Perspective on Biliary Cancers – Dunblane, Scotland.

Other external events:

- 01 – 06 June – ASCO 2024. AMMF's CEO Helen Morement and trustee Gillian Corrigan attended this internationally renowned annual oncology event in Chicago, USA. This provided an opportunity for meeting with and fostering new pharmaceutical industry relationships, and with international CCA specialists and other patient advocacy groups. They also attended the ABC-07 trial outcome presentation and, as the CEO was a member of the trial management group headed by Professor Maria Hawkins, who is a member of AMMF's Clinical and Medical Advisory Board, it was considered important for AMMF to have a presence at this event.
- 10 October: Nottingham Nurses' Event - two members of AMMF's team (Natasha Pite and Julie Cross) attended the event to showcase the work of the charity and the resources the charity has for both nurses and patients.

AMMF's CEO Awarded an Honorary Doctorate

On 17 July 2024, Helen Morement, the founder and Chief Executive of AMMF – The Cholangiocarcinoma Charity was awarded the honorary degree of Doctor of Science *honoris causa* in a graduation ceremony at the University of Nottingham in recognition of her service to medicine and science over more than two decades.

Helen was nominated for this prestigious degree by Professor Kevin Gaston, Professor of Cancer Sciences, Faculty of Medicine and Health Sciences at the University of Nottingham. The award recognises her outstanding contribution through the work of AMMF, in the field of cholangiocarcinoma.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

Professor David Bates, Professor of Oncology and Director of the University of Nottingham's Centre for Cancer Sciences, delivered an Oration in which he outlined Helen's work explaining that, as a consequence of this work, development of and access to clinical trials, surgery, information and drug therapies have improved, and that she continues to advocate for a more widespread approach for fair and equitable treatment.

Providing information for those who need it

AMMF's CEO attended the virtual NHS cancer charity briefing meetings throughout 2024. These regular meetings have proved helpful and informative, providing details of new developments in NHS processes and policies in a timely manner. AMMF's Medical and Clinical Advisors are contacted on a regular basis for help and advice on how best to handle the more difficult patient queries the charity receives, and for up to date information on clinical trials.

AMMF's website continued to be updated regularly, and provides information on all aspects of cholangiocarcinoma, including treatments and specialists, the advances being made and, importantly, there is a comprehensive list of the clinical trials that are available and recruiting in the UK, which is proving a valuable resource to healthcare professionals and patients. www.ammf.org.uk

The charity uses a number of social media platforms – Facebook, X (formerly Twitter), Instagram, LinkedIn. These are each kept up to date with daily information of importance and relevance to supporters. The number of followers on each continues to grow, with Facebook in particular now at over 6,300 followers.

AMMF's three private, member only, support groups on Facebook, Cholangiocarcinoma Support – UK and Europe: for Patients and Carers, for Patients Only, and for those bereaved, continue to grow, The groups provide an invaluable resource for patients and their loved ones and, moderated by three knowledgeable volunteers, each group is a safe and private space in which to share information, and to help and support each other.

The requirement from individual patients and family members for specific information regarding specialist consultants and treatments continues to increase. With the wider awareness of the charity, increasing incidence and growing recognition of cholangiocarcinoma, it is anticipated this area of work will continue to grow.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

As we look to 2025 ...

The Rethink Liver Cancer Campaign and Westminster Reception 2025

The Rethink Liver Cancer campaign is ongoing and will continue into 2025, especially during February's Cholangiocarcinoma Awareness Month when we will be holding a further reception in Westminster, in the House of Commons Churchill Room. The event will be hosted by Mary Glendon, MP for Newcastle upon Tyne East & Wallsend. We hope those who took part in the Faces of Cholangiocarcinoma event in December 2024 will attend, to add strength to the charity's ask of those with the power to change policy for a 'fairer deal faster' for all those diagnosed with cholangiocarcinoma.

Centres of CCA Expertise

The outcomes of the CCA data project and the publication of the new BSG Guidelines for the Diagnosis and Management of CCA gave AMMF the ammunition to begin work towards building the case for Centres of CCA Expertise. During 2024, a working group of specialists in CCA has joined with AMMF in this work, and in planning a hospital audit to ascertain the numbers of those diagnosed with CCA and the treatments they actually receive.

AMMF's Hybrid European Cholangiocarcinoma Conference 2025

The 2025 conference will take place **07 – 09 May** with a global faculty and co-chairs, Dr Heinz-Josef Klumpfen and Ms Rachel Guest, two internationally renowned specialists at the forefront of the CCA world.

And Finally

AMMF has grown steadily over the years and, with the continued help of loyal fundraisers and supporters, sponsor and advisors, we will continue our work and remain fully committed to working towards a far better future for all those diagnosed with cholangiocarcinoma.

At the heart of everything we do is the cholangiocarcinoma patient and their families, and each and every day all of us at AMMF strive towards that improved future for all those diagnosed with this most challenging of cancers. AMMF will continue its work until that goal is reached.

Financial review

Financial review and reserves policy

The charity has continued to strengthen its financial position during the year.

The charity ensures that sufficient reserves are retained in an appropriate form to fund its current obligations.

Where specific research projects have been secured, the trustees designate sufficient unrestricted reserves to cover the expected future grants payable over the term of the research project.

**AMMF- The Cholangiocarcinoma Charity
Trustees' Report**

Note 15 to the financial statements details the movement on restricted and unrestricted funds during the accounting period. Of total funds, £1,112,245 is freely available because the balance has a restriction for other purposes. Restricted funds totalled £147,539 and total funds for the period were £1,259,784.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes an incorporated charity.

Approved by order of the board of trustees on^{25 November 2025} and signed on its behalf by:

.....*Noel Corrigan*..... Noel Corrigan – Chair of Trustees

AMMF - The Cholangiocarcinoma Charity

Statement of Trustees' Responsibilities

The trustees (who are also the directors of AMMF - The Cholangiocarcinoma Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". The report and accounts have been prepared in accordance with the provisions in the Companies Act 2006 relating to small companies.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including its income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that can disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

AMMF - The Cholangiocarcinoma Charity

Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma Charity

Opinion

We have audited the financial statements of AMMF - The Cholangiocarcinoma Charity (the 'charity') for the year ended 31 January 2025, which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows, and Notes to the Financial Statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 January 2025 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Comparative period

The financial statements for the year ended 31 January 2024 were subject to an independent examination and not an audit. Accordingly, the comparative information presented does not include an auditor's opinion.

AMMF - The Cholangiocarcinoma Charity

Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma Charity

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

AMMF - The Cholangiocarcinoma Charity

Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma Charity

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report (incorporating the Directors' Report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities (set out on page 14), the trustees (who are also the directors of the charity for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with regulations made under section 154 of that Act.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

AMMF - The Cholangiocarcinoma Charity

Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma Charity

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows;

- The engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations.
- We identified the laws and regulations applicable to the charity through discussions with Trustees and other management, and from our knowledge and experience of the charity sector.
- We focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations for the charity, data protection, employment and health and safety legislation.
- We assessed the extent of compliance with the laws and regulations identified above through making enquiries of management.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur by;

- Making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud.
- Considering the internal controls in place to mitigate the risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we;

- Performed analytical procedures to identify any unusual or unexpected relationships
- Tested journal entries to identify unusual transactions
- Investigated the rationale behind significant or unusual transactions

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Edmund Carr LLP

.....
Edmund Carr LLP
Statutory Auditor

146 New London Road
Chelmsford
Essex
CM2 0AW

AMMF - The Cholangiocarcinoma Charity

**Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma
Charity**

Date: 26 November 2025

Edmund Carr LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

AMMF - The Cholangiocarcinoma Charity

Statement of Financial Activities for the Year Ended 31 January 2025 (Including Income and Expenditure Account and Other Comprehensive Income)

					(As restated)
	Note	Unrestricted £	Restricted £	Total 2025 £	Total 2024 £
Income and Endowments from:					
Donations and legacies	2	756,689	262,781	1,019,470	927,831
Other trading activities	3	6,422	-	6,422	12,470
Investment income	4	19,929	-	19,929	11,854
Total income		<u>783,040</u>	<u>262,781</u>	<u>1,045,821</u>	<u>952,155</u>
Expenditure on:					
Raising funds		2,703	-	2,703	6,271
Charitable activities	5	516,091	302,638	818,729	876,359
Total expenditure		<u>518,794</u>	<u>302,638</u>	<u>821,432</u>	<u>882,630</u>
Net income/(expenditure)		264,246	(39,857)	224,389	69,525
Transfers between funds		<u>(106,800)</u>	<u>106,800</u>	-	-
Net movement in funds		157,446	66,943	224,389	69,525
Reconciliation of funds					
Total funds brought forward		<u>954,799</u>	<u>80,596</u>	<u>1,035,395</u>	<u>965,870</u>
Total funds carried forward	17	<u><u>1,112,245</u></u>	<u><u>147,539</u></u>	<u><u>1,259,784</u></u>	<u><u>1,035,395</u></u>

All of the charity's activities derive from continuing operations during the above two periods.

AMMF - The Cholangiocarcinoma Charity

(Registration number: CEO28473)

(Charity number: 1198095)

Balance Sheet as at 31 January 2025

	Note	2025 £	(As restated) 2024 £
Fixed assets			
Tangible assets	10	7,783	4,219
Current assets			
Stocks	11	9,839	6,635
Debtors	12	85,287	69,633
Cash at bank and in hand	13	<u>1,394,776</u>	<u>1,142,072</u>
		1,489,902	1,218,340
Creditors: Amounts falling due within one year	14	<u>(237,901)</u>	<u>(187,164)</u>
Net current assets		<u>1,252,001</u>	<u>1,031,176</u>
Net assets		<u>1,259,784</u>	<u>1,035,395</u>
Funds of the charity:			
Restricted income funds			
Restricted funds	17	147,539	80,596
Unrestricted income funds			
Unrestricted funds		<u>1,112,245</u>	<u>954,799</u>
Total funds	17	<u>1,259,784</u>	<u>1,035,395</u>

The financial statements on pages 20 to 33 were approved by the trustees, and authorised for issue on 25 November 2025 and signed on their behalf by:

Noel Corrigan

.....
Mr Noel Corrigan
Chairman

AMMF - The Cholangiocarcinoma Charity

Statement of Cash Flows for the Year Ended 31 January 2025

	Note	2025 £	(As restated) 2024 £
Cash flows from operating activities			
Net movement in funds per SOFA		224,389	69,525
Adjustments			
Depreciation		3,432	2,551
Investment income	4	<u>(19,929)</u>	<u>(11,854)</u>
		207,892	60,222
Working capital adjustments			
(Increase)/decrease in stocks	11	(3,204)	751
Increase in debtors	12	(15,654)	(29,422)
Increase in creditors	14	25,737	127,776
Increase in deferred income		<u>25,000</u>	<u>-</u>
Net cash flows from operating activities		<u>239,771</u>	<u>159,327</u>
Cash flows from investing activities			
Interest receivable and similar income	4	19,929	11,854
Purchase of tangible fixed assets	10	<u>(6,996)</u>	<u>(155)</u>
Net cash flows from investing activities		<u>12,933</u>	<u>11,699</u>
Net increase in cash and cash equivalents		252,704	171,026
Cash and cash equivalents at 1 February		<u>1,142,072</u>	<u>971,046</u>
Cash and cash equivalents at 31 January		<u>1,394,776</u>	<u>1,142,072</u>

All of the cash flows are derived from continuing operations during the above two periods.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

1 Accounting policies

Statement of compliance

The accounts (financial statements) have been prepared in accordance with the statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 and the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Practice as it applies from 1 January 2019.

The accounts (financial statements) have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Basis of preparation

AMMF - The Cholangiocarcinoma Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Deferred income

Deferred income represents amounts received for future periods and is released to incoming resources in the period for which, it has been received. Such income is only deferred when:

- The donor specifies that the grant or donation must only be used in future accounting periods; or
- The donor has imposed conditions which must be met before the charity has unconditional entitlement.

Investment income

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Tangible fixed assets

Individual fixed assets costing £50.00 or more are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Computer equipment	33%

Stock

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell, after due regard for obsolete and slow moving stocks. Cost is determined using the first-in, first-out (FIFO).

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

2 Income from donations and legacies

	Unrestricted funds £	Restricted funds £	Total funds £
Donations and legacies	756,689	262,781	1,019,470
Total for 2025	756,689	262,781	1,019,470
(As restated) Total for 2024	699,595	228,236	927,831

3 Income from other trading activities

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	Unrestricted funds £	Restricted funds £	Total funds £
Trading income;			
Shop income	6,422	-	6,422
Total for 2025	6,422	-	6,422
Total for 2024	12,470	-	12,470

4 Investment income

	Unrestricted funds £	Total funds £
Interest receivable and similar income;		
Interest receivable on bank deposits	19,929	19,929
Total for 2025	19,929	19,929
Total for 2024	11,854	11,854

5 Expenditure on charitable activities

		Unrestricted funds £	Restricted £	Total 2025 £	(As restated) Total 2024 £
European Conference costs		274,114	302,638	576,752	514,849
Grants to institutions		90,771	-	90,771	234,248
European Website costs		-	-	-	9,582
Depreciation, amortisation and other similar costs		3,432	-	3,432	2,551
Staff costs		133,689	-	133,689	109,782
Governance costs	6	14,085	-	14,085	5,347
		516,091	302,638	818,729	876,359

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

6 Analysis of governance and support costs

Governance costs

	Total 2025 £	Total 2024 £
Audit fees		
Audit of the financial statements	12,600	-
Independent examiner fees		
Accounts and independent examination	-	3,900
Payroll fees	284	878
Bookeeping fees	1,201	569
	<u>14,085</u>	<u>5,347</u>

7 Net incoming/outgoing resources

Net incoming resources for the year include:

	2025 £	2024 £
Audit fees	12,600	-
Depreciation of fixed assets	3,432	2,551

8 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Mr Harold Corrigan

£890 (2024: £616) of expenses were reimbursed to Mr Harold Corrigan during the year.

Mr Noel Corrigan

£767 (2024: £205) of expenses were reimbursed to Mr Noel Corrigan during the year.

Mr Tom Morement

£479 (2024: £Nil) of expenses were reimbursed to Mr Tom Morement during the year.

Mrs Gillian Corrigan

£2,648 (2024: £Nil) of expenses were reimbursed to Mrs Gillian Corrigan during the year.

9 Staff costs

The aggregate payroll costs were as follows:

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	2025 £	2024 £
Staff costs during the year were:		
Wages and salaries	123,528	104,451
Social security costs	7,796	3,776
Pension costs	2,365	1,555
	133,689	109,782

The monthly average number of persons (including senior management / leadership team) employed by the charity during the year expressed by head count was as follows:

	2025 No	2024 No
Employees	4	4

No employee received emoluments of more than £60,000 during the year.

The total employee benefits of the key management personnel of the charity were £52,463.

10 Tangible fixed assets

	Computer equipment £	Total £
Cost		
At 1 February 2024	13,135	13,135
Additions	6,996	6,996
Disposals	(3,682)	(3,682)
At 31 January 2025	16,449	16,449
Depreciation		
At 1 February 2024	8,916	8,916
Charge for the year	3,432	3,432
Eliminated on disposals	(3,682)	(3,682)
At 31 January 2025	8,666	8,666
Net book value		
At 31 January 2025	7,783	7,783
At 31 January 2024	4,219	4,219

11 Stock

	2025 £	2024 £
Stocks	9,839	6,635

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

12 Debtors

	2025	(As restated) 2024
	£	£
Trade debtors	18,800	-
Prepayments	54,279	46,231
Accrued income	12,208	23,402
	<u>85,287</u>	<u>69,633</u>

13 Cash and cash equivalents

	2025	2024
	£	£
Cash on hand	202	25
Cash at bank	1,394,574	1,142,047
	<u>1,394,776</u>	<u>1,142,072</u>

14 Creditors: amounts falling due within one year

	2025	(As restated) 2024
	£	£
Trade creditors	13,394	8,816
Accruals for grants	168,938	168,937
Other taxation and social security	3,945	1,077
Accruals	26,624	8,334
Deferred income	25,000	-
	<u>237,901</u>	<u>187,164</u>
		2025
Resources deferred in the period		<u>£ 25,000</u>

Included within deferred income is £25,000 for sponsorship for the 2025 AMMF Conference.

15 Obligations under leases and hire purchase contracts

The total value of future minimum lease payments was as follows:

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	2025 £	2024 £
Within one year	23,460	24,720
In two to five years	19,425	12,360
In over five years	4,770	-
	47,655	37,080

16 Contingent liabilities

At 31 January 2025 grants of £161,999 (2024: £101,645) had been awarded for which conditions for the recognition in the year had not been met.

17 Funds

Current year:

	Balance at 1 February 2024 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 January 2025 £
Unrestricted funds					
General Funds	954,799	783,040	(518,794)	(106,800)	1,112,245
Restricted					
Restricted Research Funds	21,120	11,818	-	-	32,938
European Website Project	23,606	5,000	(758)	-	27,848
European Conference 2024	-	140,963	(247,763)	106,800	-
External Projects	35,870	105,000	(54,117)	-	86,753
Total restricted	80,596	262,781	(302,638)	106,800	147,539
Total funds	1,035,395	1,045,821	(821,432)	-	1,259,784

Prior year:

	Balance at 1 February 2023 £	Incoming resources £	Resources expended £	Transfers £	(As restated) Balance at 31 January 2024 £
Unrestricted funds					
Unrestricted funds					
General Funds	876,124	723,919	(613,321)	(31,923)	954,799

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	Balance at 1 February 2023 £	Incoming resources £	Resources expended £	Transfers £	(As restated) Balance at 31 January 2024 £
Restricted					
Restricted Research Funds	21,120	-	-	-	21,120
European Website Project	33,626	-	(10,020)	-	23,606
European Conference 2023	35,000	124,923	(191,846)	31,923	-
External Projects	-	103,313	(67,443)	-	35,870
Total restricted funds	<u>89,746</u>	<u>228,236</u>	<u>(269,309)</u>	<u>31,923</u>	<u>80,596</u>
Total funds	<u>965,870</u>	<u>952,155</u>	<u>(882,630)</u>	<u>-</u>	<u>1,035,395</u>

The specific purposes for which the funds are to be applied are as follows:

Restricted research funds represent donations where the donor has requested that their donation be used for research purposes only. These donations are held within restricted funds until utilised in part or in whole to fund a cholangiocarcinoma research project which the charity has committed to support.

Restricted funds for each of the major projects AMMF undertakes represent those donations or sponsorships where the donor has requested that their monies be used for that particular project only. Those funds are held as restricted funds until used in full or in part to complete the project for which they were given.

Restricted funds for the major, external projects AMMF undertakes represent sponsorships to support only those individual specific projects for which the funding has been given. The number of such projects varies from year to year.

The transfer of £106,800 represents restricted projects and events funded from unrestricted funds due to a shortfall in funding received.

18 Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total funds at 31 January 2025 £
Tangible fixed assets	7,783	-	7,783
Current assets	1,342,363	147,539	1,489,902
Current liabilities	<u>(237,901)</u>	<u>-</u>	<u>(237,901)</u>
Total net assets	<u>1,112,245</u>	<u>147,539</u>	<u>1,259,784</u>

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	Unrestricted funds £	Restricted funds £	(As restated) Total funds at 31 January 2024 £
Tangible fixed assets	4,219	-	4,219
Current assets	1,137,744	80,596	1,218,340
Current liabilities	<u>(187,164)</u>	<u>-</u>	<u>(187,164)</u>
Total net assets	<u>954,799</u>	<u>80,596</u>	<u>1,035,395</u>

19 Related party transactions

There were no related party transactions in the year.

20 Prior period adjustment

Restatement of prior period balances has taken place, the adjustments were made due to under provided accrued income and accruals in the Year Ended 31 January 2024. As a result, in the comparative figures, donations and legacies income and accrued income have increased by £23,402 and charitable activity expenditure and accruals have increased by £4,434.

Also, the prior year contingent liability was also understated. The comparative in note 16 has been restated and increased by £14,325. This has no affect on the prior year's surplus or balance sheet.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

The following page does not form part of the statutory financial statements.

AMMF - The Cholangiocarcinoma Charity

Detailed Statement of Financial Activities for the Year Ended 31 January 2025

	Total 2025 £	Total 2024 £
Income and Endowments from:		
Donations and legacies	1,019,470	927,831
Other trading activities	6,422	12,470
Investment income	19,929	11,854
Total income	<u>1,045,821</u>	<u>952,155</u>
Expenditure on:		
Raising funds	(2,703)	(6,271)
Charitable activities	(818,729)	(876,359)
Total expenditure	<u>(821,432)</u>	<u>(882,630)</u>
Net income	<u>224,389</u>	<u>69,525</u>
Net movement in funds	224,389	69,525
Reconciliation of funds		
Total funds brought forward	<u>1,035,395</u>	<u>965,870</u>
Total funds carried forward	<u><u>1,259,784</u></u>	<u><u>1,035,395</u></u>

This page does not form part of the statutory financial statements.

AMMF - THE CHOLANGIOMYOCARCINOMA CHARITY

England & Wales - Charity number 1198095

Accounts

Charity registration number: 1198095
Company registration number: CEO28473

AMMF - The Cholangiocarcinoma Charity

(A Charitable Incorporated Organisation)

Annual Report and Financial Statements

for the Year Ended 31 January 2024

Edmund Carr LLP
Chartered Accountants & Statutory Auditor
146 New London Road
Chelmsford
Essex
CM2 0AW

AMMF - The Cholangiocarcinoma Charity

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Statement of Cash Flows	12
Notes to the Financial Statements	13 to 21

AMMF - The Cholangiocarcinoma Charity

Reference and Administrative Details

Chairman	Mr Noel Corrigan
Trustees	Mrs Gillian Corrigan Mr Harold Corrigan Mr Tom Morement
Senior Management / Leadership Team	Mrs Helen Morement, CEO
Registered Office	Enterprise House Bassingbourn Road Stansted Essex CM24 1QW The charity is incorporated in England and Wales.
Charity Registration Number	1198095
Company Registration Number	CEO28473
Independent Examiner	Edmund Carr LLP Chartered Accountants & Statutory Auditor 146 New London Road Chelmsford Essex CM2 0AW

AMMF – The Cholangiocarcinoma Charity

Trustees’ report for the Year Ended 31 January 2024

The trustees present their report with the financial statements of the charity for the year ended 31 January 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

AMMF – The Cholangiocarcinoma Charity was registered with the Charity Commission as a Charitable Incorporated Organisation (CIO) during the year 2022. The CIO registered number with the Charity Commission is 1198095.

The charity was originally registered in 2002 under the name, The Alan Morement Memorial Fund (working title, AMMF) and was an unincorporated charity with the registration number 1091915.

However, because of the continuing growth of the charity, AMMF’s trustees decided that it should transition as a legal entity from unincorporated registered charity status to that of a Charitable Incorporated Organisation (CIO). This involved lengthy work with the Charity Commission, and the new CIO status was approved on 01 June, 2022. At that point the work and all assets of the original charity passed to the new CIO charity.

The original charity and its registered number 1091915 will always remain in existence, with all records submitted to the Charity Commission still available on the Commission’s website, but this entity will now remain in the background.

The new CIO is officially known as: AMMF – The Cholangiocarcinoma Charity, with the registered number: 1198095.

AMMF’s aims and objectives remain unchanged and the charity’s work has continued seamlessly and without interruption since the inception of the CIO on 01 June 2022.

OBJECTIVES AND ACTIVITIES

AMMF’s MISSION

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

AMMF’s VISION

A world where people can live their lives free of cholangiocarcinoma (CCA) as a life-threatening disease.

AMMF – the Cholangiocarcinoma Charity is the only charity in the UK solely dedicated to cholangiocarcinoma (bile duct cancer). AMMF works nationally throughout the UK, as well as in Europe, and collaborates globally.

AMMF is wholly committed nationally and internationally to tackling the devastating cancer, cholangiocarcinoma (CCA) on all fronts and, ultimately, to help find a cure, through:

- Support - Providing information to individuals or groups to support a patient or loved one along their journey
- Empowerment – Empowering patients and their loved ones to advocate for themselves, seek better care, new treatment options and second opinions
- Access – Advocating for patients to ensure they have access to the latest treatment options and a minimum standard of care appropriate to them
- Awareness – Raising awareness of cholangiocarcinoma to support earlier diagnosis, fair and equal access to treatments, including new treatment approaches
- Research – Encouraging and supporting continued research into causes, diagnostics, and new treatment options for those with cholangiocarcinoma
- Policy – Working towards ensuring health care policies reflect the needs of those with cholangiocarcinoma

AMMF – The Cholangiocarcinoma Charity

Trustees' report for the Year Ended 31 January 2024 (continued)

Cholangiocarcinoma is under-represented and under-funded across all areas, including policy, services, and research. It is a poorly understood and under researched disease which is increasing in incidence not only in the UK but throughout the world. Lack of awareness and the difficulties of achieving clear and accurate diagnosis, mean that most are at an advanced stage and inoperable at time of their diagnosis.

Whilst surgery remains the only potentially curative treatment, there is now palliative chemotherapy and immunotherapy, and a growing number of clinical trials, in particular those investigating further targeted therapies and immunotherapies. However, a diagnosis of inoperable cholangiocarcinoma remains invariably fatal, and this is a situation that has not changed in decades. AMMF is committed to working to change this scenario, nationally and internationally.

Resolute in bringing about improvement for the cholangiocarcinoma patient, AMMF continues to work closely with patients and their carers, clinicians, healthcare professionals, researchers, and policy makers, as well as actively collaborating globally.

During the year 2023, the charity continued its advocacy work, especially in helping those with cholangiocarcinoma to navigate their way to continue essential treatments wherever possible.

Raising Awareness

AMMF's Cholangiocarcinoma Data Project

Lack of robust data for cholangiocarcinoma (CCA) has long been seen by AMMF as a major reason why there is so little awareness of this cancer, and so little progress. Robust data are essential to drive policy, to encourage research funding, to stimulate interest, and so much more.

AMMF's Cholangiocarcinoma Data project, of enormous importance to the charity's work towards improved awareness not only of CCA itself, but the number of unmet needs in this area, finally completed during 2023. We have now been able to share its important findings, some of which confirmed what we already knew, and some findings we had previously not been aware of.

Key findings include:

- CCA is no longer as rare as previously considered, it is a growing, untargeted problem.
- More than half of those diagnosed with CCA received no cancer specific treatment at all.
- There have been no improvements in CCA survival rates in decades.
- People from the most deprived backgrounds were found to be almost 40% less likely to survive after a CCA diagnosis compared to the least deprived.

This data work has resulted in three papers, published in scientific journals:

- **Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006–2017** For the full paper in World Journal of Gastroenterology, see: <https://www.wjgnet.com/1007-9327/full/v29/i24/3825.htm>
- **Cholangiocarcinoma across England: a national study of temporal changes in incidence, survival and routes to diagnosis by region and socioeconomic deprivation.** For the full paper in JHep Reports, see: [https://www.jhep-reports.eu/article/S2589-5559\(23\)00314-2/fulltext](https://www.jhep-reports.eu/article/S2589-5559(23)00314-2/fulltext)
- **Cohort study to assess geographical variation in cholangiocarcinoma treatment in England** For the full paper in World Journal of Gastrointestinal Oncology, see: <https://www.wjgnet.com/1948-5204/full/v15/i12/2077.htm>

AMMF – The Cholangiocarcinoma Charity

Trustees' report for the Year Ended 31 January 2024 (continued)

Rethink Liver Cancer Campaign and White Paper

Backed by the findings of AMMF's CCA data project, October 2023's Liver Cancer Awareness Month saw the launch of the charity's major "Rethink Liver Cancer" campaign with social media coverage and a press release.

The campaign launch and the press release gained significant media attention, most notably in: Mail Online / Mail on Sunday, The Times and The Express

To coincide with the launch of the campaign, AMMF prepared a White Paper, with a foreword from Professor Shahid Khan, Imperial College London, outlining the findings of the data project and with specific asks for improvements to be made across the board.

A Westminster reception is planned for February 2024, where AMMF will share the details of the White Paper and its asks with those within government and the NHS who can change policy, and have the ability to bring about improvements for those diagnosed with cholangiocarcinoma.

For the Rethink Liver Cancer Campaign details and the White Paper, see: <https://ammf.org.uk/rethink-liver-cancer/>

AMMF's Hybrid European Cholangiocarcinoma Conference May 2023

AMMF was delighted to welcome two internationally renowned specialists at the forefront of the CCA world, Professor John Bridgewater (UK) and Professor Lorenza Rimassa (Italy), as co-chairs of the 2023 conference. They expertly hosted a faculty of more than 40 international speakers and managed some challenging Q & A sessions, all exploring the conference theme – Innovation.

The full programme and all conference presentations from the three days were recorded and remain available to view via AMMF website. See: <https://ammf.org.uk/ammf-conference-2023/>

Global Cholangiocarcinoma Alliance

The Global Cholangiocarcinoma Alliance (GCA) was established at AMMF's international workshop held in London in 2018. The aim of the Alliance is to provide a united voice through international collaboration, to provide a platform on which to build links and exchange knowledge in order to raise the global awareness of CCA, to improve the education of both healthcare professionals and patients, and to address current challenges.

Since the GCA's inception in 2018, AMMF has continued to act as the not-for-profit partner in this venture, and AMMF's CEO Helen Morement is a co-chair on the international steering committee.

During 2023 the secretariat of the GCA sat with the healthcare communications agency AXON, who managed the bespoke website and social media accounts, and also the organisation of the annual World Cholangiocarcinoma Day, on 15 February 2023.

Public Benefit

In forming the charity's objectives and planning the activities, the trustees have considered the Charity Commission's guidance in respect of public benefit.

AMMF – The Cholangiocarcinoma Charity

Trustees' report for the Year Ended 31 January 2024 (continued)

ACHIEVEMENTS AND PERFORMANCE

AMMF's Research Awards

AMMF remains committed to supporting research into cholangiocarcinoma. In 2023, based on the advice of AMMF's Scientific Advisory Board awards were offered and accepted by the following to support their research into cholangiocarcinoma:

University of Glasgow (Professor Chiara Braconi & Dr Jen Morton) – AMMF ref: 2023/218

“Identifying therapeutic opportunities for Biliary Cancers by investigating the role of Monocytes in drug response”

Award: £99,464 (to be given in two instalments)

University of Oxford (Dr Shijie Cai) – AMMF Ref: 2023/219

“Normal cholangiocyte containment of cholangiocarcinoma through metabolic and transcriptomic regulation”

Award: £56,002.27 (to be given in one instalment)

University of Edinburgh (Professor Ed Jarman & Paula Olaizola) – AMMF Ref: 2023/221

“Does retinol from hepatic stellate cells fuel tumour cells during cholangiocarcinoma initiation”.

Award: £50,000 (to be given in three instalments)

Withdrawn award offer: An award offer was also made to the Karolinska Institute, Sweden but was withdrawn by AMMF as the institute was unable to fully comply with the IP requirements as noted in AMMF's Terms and Conditions of Research Grants:

Karolinska Institute, Sweden (Timea Szejerczés) - AMMF Ref: 2023/220

Work on the 'Molecular Characterisation of CCA' in the total amount of £29,000.

GRANT OFFER WITHDRAWN 13.10.2023

During 2023 the following payments were made re existing awards:

Sapienza University of Rome - AMMF Ref: 2022/211

£14,764.32 was paid on 15.12.2023 representing the first instalment of the award of £35,000 agreed to fund the work of Professor Carmine Mancone in, “The role of THBS1, THBS2 and PEDF in the lymphatic dissemination of the intrahepatic cholangiocarcinoma: identification of downstream signalling”

University of Nottingham - AMMF Ref: 2022/215

£22,000 was paid on 07.11.2023 representing the full amount of the award made to Professors Sheela Jayaraman, Anna Grabowska, Kevin Gaston, to fund their work, “Combination therapies for cholangiocarcinoma”

AMMF's External Activities

The charity is recognized widely, nationally and internationally, amongst both the general public and within medical circles, for its work in the field of cholangiocarcinoma, and is frequently invited to become part of study groups and advisory boards, for example, the working group for Liver Transplantation for Cholangiocarcinoma, and the executive committee of Cholangiocarcinoma-UK.

AMMF is also a member of the European Network for the Study of Cholangiocarcinoma (ENS-CCA), an association of research groups from across Europe and beyond, actively working on basic, translational, and clinical research into cholangiocarcinoma, and AMMF's CEO is chair of the ENS-CCA Patient Advocacy Committee.

AMMF – The Cholangiocarcinoma Charity

Trustees' report for the Year Ended 31 January 2024 (continued)

AMMF continues to be an active member of Cancer52, the alliance of rare and less common cancer organisations in the UK. AMMF's CEO, Helen Morement was appointed a board director of Cancer52 in 2014, and has continued in that role since then. She also acted as interim co-chair during the year (with fellow Cancer52 board member, Rebecca Porta, CEO of The Urology Foundation) whilst a new chair of trustees was sought. Through membership of Cancer52, AMMF is enabled to have a presence and a voice within every national cancer initiative and AMMF's trustees see this as providing an important opportunity to work more closely with this increasingly influential organisation, and in identifying priority challenges and opportunities for all those in the rare and less common cancers community.

AMMF involvement in BSG Guidelines for the Diagnosis and Management of Cholangiocarcinoma

Commissioned by the BSG (British Society of Gastroenterology) and published in GUT in September 2023, these are the most comprehensive guidelines for the diagnosis and management of CCA since 2012.

Headed by Professor Shahid Khan, Imperial College London, the guidelines were prepared by a multidisciplinary writing committee of UK experts from various specialties involved in the diagnosis and management of CCA, each writing a section on their own area of expertise, and AMMF was delighted to be invited to contribute the section on Patient/Public involvement.

For more information and the guidelines, see: <https://ammf.org.uk/guidelines-for-the-diagnosis-and-management-of-cholangiocarcinoma/>

SMC and NICE - new therapy appraisals

During 2023 AMMF was invited, both as a patient facing organisation and a patient advocate, to submit written and oral statements in support of new therapy appraisals, by both the SMC (Scottish Medicines Consortium) and NICE (National Institute for Care and Excellence). We are especially grateful to two AMMF supporters with first-hand experience of CCA, Andrea Sheardown and Andy Clay, who also took part in the NICE appraisals and, acting as patient advocates, spoke on behalf of all those diagnosed with CCA.

New therapies for cholangiocarcinoma approved during 2023:

- Pembrolizumab – a 2nd line treatment for those with high microsatellite instability or mismatch repair deficiency CCA
- Durvalumab with Gemcitabine and Cisplatin – an immunotherapy given with a combination of chemotherapies as a new 1st line treatment.
- Ivosidenib – a 2nd line treatment for those with an IDH1 mutation.

Following on from the approval of pemigatinib in 2022 (a 2nd line treatment for those with an FGFR2 fusion), which opened the door to molecular profiling for all diagnosed with CCA, these appraisals during 2023 represent important additions to the small number of therapies available for cholangiocarcinoma to this point.

Other events

As the charity expands its work throughout the UK and into Europe, AMMF's CEO attended and spoke about cholangiocarcinoma and the work of AMMF at a number of national and international conferences during the year, including at the ENS-CCA (European Network for the Study of Cholangiocarcinoma) in Rome, The ILCA (International Liver Cancer Association) conference in Amsterdam, the ESMO (European Society of Medical Oncology) Advanced Course on CCA in Barcelona, and honoured to be invited to speak at a reception held by the Spanish Ambassador to the Holy See in Rome.

AMMF – The Cholangiocarcinoma Charity

Trustees' report for the Year Ended 31 January 2024 (continued)

Providing information for those who need it

AMMF's CEO attended monthly virtual NHS cancer charity briefing meetings throughout 2023. These regular meetings, which began during the pandemic, are proving informative, providing details of new developments in NHS processes and policies in a timely manner. AMMF's Medical and Clinical Advisors are contacted on a regular basis for help and advice on how best to handle the more difficult patient queries the charity receives, and for up to date information on clinical trials.

AMMF's website continued to be updated regularly, and provides information on all aspects of cholangiocarcinoma, including treatments and specialists, the advances being made and, importantly, there is a comprehensive list of the clinical trials that are available and recruiting in the UK, which is proving a valuable resource to medics and patients. www.ammf.org.uk

The charity's active social media platforms kept supporters up to date with information of importance and relevance to them throughout the year. AMMF's Facebook page now has some 6,000 followers, and the following on X (formerly Twitter), Instagram and LinkedIn continues to grow.

AMMF now has three private, member only, support groups on Facebook, Cholangiocarcinoma Support – UK and Europe: for Patients and Carers, for Patients Only, and for those bereaved. These have been extremely well received by a growing number of users – the main forum, for Patients and Carers, has over 1,200 users. These groups are proving an invaluable resource for patients to share information, and for them to help and support each other.

The requirement from individual patients and family members for specific information regarding specialist consultants and treatments continues to increase. With the wider awareness of the charity, increasing incidence and growing recognition of cholangiocarcinoma, it is anticipated this area of work will continue to grow.

As we look to 2024 ...

The Rethink Liver Cancer Campaign and a Westminster Reception

The Rethink Liver Cancer campaign is ongoing and will continue into 2024, especially during February's Cholangiocarcinoma Awareness Month when we will be holding a reception in Westminster, in the House of Commons Terrace Pavilion Room. This event will be hosted by Elliot Colburn MP, Chair of the APPG on Cancer. At that event, we will share the details of AMMF's White Paper and its asks with those who can change policy and make a difference for those diagnosed with cholangiocarcinoma.

Centres of CCA Expertise

The outcomes of the CCA data project and the publication of the new BSG Guidelines for the Diagnosis and Management of CCA have given AMMF the ammunition to begin work towards Centres of CCA Expertise. First steps have been taken, a working group of some of the top experts in CCA has been set up, and we expect the project to gain momentum during 2024.

AMMF's Hybrid European Cholangiocarcinoma Conference

The 2024 conference will take place 08 – 10 May with an international faculty.

And Finally

AMMF has grown steadily over the years and, with the continued help of loyal fundraisers and supporters, sponsor and advisors, we will continue our work and remain fully committed to working towards a far better future for all those diagnosed with cholangiocarcinoma.

AMMF – The Cholangiocarcinoma Charity

Trustees' report for the Year Ended 31 January 2024 (continued)

At the heart of everything we do is the cholangiocarcinoma patient and their families, and each and every day all of us at AMMF strive towards that improved future for all those diagnosed with this most challenging of cancers. AMMF will continue its work until that goal is reached.

FINANCIAL REVIEW

Financial review and reserves policy

The charity has continued to strengthen its financial position during the year.

The charity ensures that sufficient reserves are retained in an appropriate form to fund its current obligations.

Where specific research projects have been secured, the trustees designate sufficient unrestricted reserves to cover the expected future grants payable over the term of the research project.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes an unincorporated charity.

Approved by order of the board of trustees on 18 November 2024 and signed on its behalf by:

Noel Corrigan
.....
Noel Corrigan – Chair of Trustees

AMMF - The Cholangiocarcinoma Charity

Independent Examiner's Report to the trustees of AMMF - The Cholangiocarcinoma Charity

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 January 2024 which are set out on pages 10 to 21.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached

Sandra Morrell

.....
Sandra Morrell FCCA
146 New London Road
Chelmsford
Essex
CM2 0AW

Date: 19 November 2024
.....

AMMF - The Cholangiocarcinoma Charity

Statement of Financial Activities for the Year Ended 31 January 2024 (Including Income and Expenditure Account and Other Comprehensive Income)

	Note	Unrestricted £	Restricted £	Total 2024 £	Total 2023 £
Income and Endowments from:					
Donations and legacies	2	676,193	228,236	904,429	1,030,491
Other trading activities	3	12,470	-	12,470	7,760
Investment income	4	11,854	-	11,854	1,397
Total income		<u>700,517</u>	<u>228,236</u>	<u>928,753</u>	<u>1,039,648</u>
Expenditure on:					
Raising funds		6,271	-	6,271	4,115
Charitable activities	5	602,616	269,309	871,925	696,366
Total expenditure		<u>608,887</u>	<u>269,309</u>	<u>878,196</u>	<u>700,481</u>
Net income/(expenditure)		91,630	(41,073)	50,557	339,167
Transfers between funds		<u>(31,923)</u>	<u>31,923</u>	-	-
Net movement in funds		59,707	(9,150)	50,557	339,167
Reconciliation of funds					
Total funds brought forward		<u>876,124</u>	<u>89,746</u>	<u>965,870</u>	<u>626,703</u>
Total funds carried forward	17	<u><u>935,831</u></u>	<u><u>80,596</u></u>	<u><u>1,016,427</u></u>	<u><u>965,870</u></u>

All of the charity's activities derive from continuing operations during the above two periods.

AMMF - The Cholangiocarcinoma Charity

(Registration number: CEO28473)
Balance Sheet as at 31 January 2024

	Note	2024 £	2023 £
Fixed assets			
Tangible assets	10	4,219	6,615
Current assets			
Stocks	11	6,635	7,386
Debtors	12	46,231	40,211
Cash at bank and in hand	13	<u>1,142,072</u>	<u>971,046</u>
		1,194,938	1,018,643
Creditors: Amounts falling due within one year	14	<u>(182,730)</u>	<u>(59,388)</u>
Net current assets		<u>1,012,208</u>	<u>959,255</u>
Net assets		<u>1,016,427</u>	<u>965,870</u>
Funds of the charity:			
Restricted income funds			
Restricted funds	17	80,596	89,746
Unrestricted income funds			
Unrestricted funds		<u>935,831</u>	<u>876,124</u>
Total funds	17	<u>1,016,427</u>	<u>965,870</u>

The financial statements on pages 10 to 21 were approved by the trustees, and authorised for issue on 18 November 2024 and signed on their behalf by:

Noel Corrigan

.....
Mr Noel Corrigan
Chairman

AMMF - The Cholangiocarcinoma Charity

Statement of Cash Flows for the Year Ended 31 January 2024

	Note	2024 £	2023 £
Cash flows from operating activities			
Net movement in funds per SOFA		50,557	339,167
Adjustments			
Depreciation		2,551	948
Investment income	4	<u>(11,854)</u>	<u>(1,397)</u>
		41,254	338,718
Working capital adjustments			
Decrease/(increase) in stocks	11	751	(264)
Increase in debtors	12	(6,020)	(28,067)
Increase/(decrease) in creditors	14	<u>123,342</u>	<u>(67,058)</u>
Net cash flows from operating activities		<u>159,327</u>	<u>243,329</u>
Cash flows from investing activities			
Interest receivable and similar income	4	11,854	1,397
Purchase of tangible fixed assets	10	<u>(155)</u>	<u>(7,563)</u>
Net cash flows from investing activities		<u>11,699</u>	<u>(6,166)</u>
Net increase in cash and cash equivalents		171,026	237,163
Cash and cash equivalents at 1 February		<u>971,046</u>	<u>733,883</u>
Cash and cash equivalents at 31 January		<u><u>1,142,072</u></u>	<u><u>971,046</u></u>

All of the cash flows are derived from continuing operations during the above two periods.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

1 Accounting policies

Statement of compliance

The accounts (financial statements) have been prepared in accordance with the statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 and the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Practice as it applies from 1 January 2019.

The accounts (financial statements) have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Basis of preparation

AMMF - The Cholangiocarcinoma Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Investment income

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Tangible fixed assets

Individual fixed assets costing £0.00 or more are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Computer equipment	33%

Stock

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell, after due regard for obsolete and slow moving stocks. Cost is determined using the first-in, first-out (FIFO).

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

2 Income from donations and legacies

	Unrestricted funds £	Restricted funds £	Total funds £
Donations receivable	642,871	228,236	871,107
Total for 2024	642,871	228,236	871,107
Total for 2023	863,852	166,639	1,030,491

3 Income from other trading activities

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

	Unrestricted funds £	Restricted funds £	Total funds £
Trading income;			
Shop income	12,470	-	12,470
Total for 2024	12,470	-	12,470
Total for 2023	7,760	-	7,760

4 Investment income

	Unrestricted funds £	Total funds £
Interest receivable and similar income;		
Interest receivable on bank deposits	11,854	11,854
Total for 2024	11,854	11,854
Total for 2023	1,397	1,397

5 Expenditure on charitable activities

		Unrestricted funds £	Restricted £	Total 2024 £	Total 2023 £
	Note				
European Conference costs		250,688	259,727	510,415	403,387
Grants to institutions		234,248	-	234,248	155,492
European Website costs		-	9,582	9,582	25,841
Workshops		-	-	-	22,077
Depreciation, amortisation and other similar costs		2,551	-	2,551	948
Staff costs		109,782	-	109,782	82,157
Governance costs	6	5,347	-	5,347	6,464
		602,616	269,309	871,925	696,366

In addition to the expenditure analysed above, there are also governance costs of £5,347 (2023 - £6,464) which relate directly to charitable activities. See note 6 for further details.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

6 Analysis of governance and support costs

Governance costs

	Total 2024 £	Total 2023 £
Independent examiner fees		
Accounts and independent examination	3,900	5,400
Payroll fees	878	408
Bookkeeping fees	569	656
	<u>5,347</u>	<u>6,464</u>

7 Net incoming/outgoing resources

Net incoming resources for the year include:

	2024 £	2023 £
Depreciation of fixed assets	<u>2,551</u>	<u>948</u>

8 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Mr Harold Corrigan

£616 (2023: £Nil) of expenses were reimbursed to Mr Harold Corrigan during the year.

Mr Noel Corrigan

£205 (2023: £Nil) of expenses were reimbursed to Mr Noel Corrigan during the year.

9 Staff costs

The aggregate payroll costs were as follows:

	2024 £	2023 £
Staff costs during the year were:		
Wages and salaries	104,451	78,173
Social security costs	3,776	3,060
Pension costs	1,555	924
	<u>109,782</u>	<u>82,157</u>

No employee received emoluments of more than £60,000 during the year.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

10 Tangible fixed assets

	Computer equipment £	Total £
Cost		
At 1 February 2023	13,578	13,578
Additions	155	155
Disposals	(598)	(598)
At 31 January 2024	13,135	13,135
Depreciation		
At 1 February 2023	6,963	6,963
Charge for the year	2,551	2,551
Eliminated on disposals	(598)	(598)
At 31 January 2024	8,916	8,916
Net book value		
At 31 January 2024	4,219	4,219
At 31 January 2023	6,615	6,615

11 Stock

	2024 £	2023 £
Stocks	6,635	7,386

12 Debtors

	2024 £	2023 £
Trade debtors	-	2,190
Prepayments	46,231	36,793
Other debtors	-	1,228
	46,231	40,211

13 Cash and cash equivalents

	2024 £	2023 £
Cash on hand	25	383
Cash at bank	1,142,047	970,663
	1,142,072	971,046

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

14 Creditors: amounts falling due within one year

	2024 £	2023 £
Trade creditors	8,816	48,530
Accruals for grants	168,937	-
Other taxation and social security	1,077	5,458
Accruals	3,900	5,400
	182,730	59,388

15 Obligations under leases and hire purchase contracts

The total value of future minimum lease payments was as follows:

	2024 £	2023 £
Within one year	24,720	24,720
In two to five years	12,360	37,080
	37,080	61,800

16 Contingent liabilities

At 31 January 2024 grants of £87,320 had been awarded for which conditions for the recognition in the year had not been met.

17 Funds

Current year:

	Balance at 1 February 2023 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 January 2024 £
Unrestricted funds					
General Funds - all funds	876,124	700,517	(608,887)	(31,923)	935,831
Restricted					
Restricted Research Funds	21,120	-	-	-	21,120
European Website Project	33,626	-	(10,020)	-	23,606
European Conference 2023	35,000	124,923	(191,846)	31,923	-
External Projects	-	103,313	(67,443)	-	35,870
Total restricted	89,746	228,236	(269,309)	31,923	80,596
Total funds	965,870	928,753	(878,196)	-	1,016,427

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

Prior year:

	Balance at 1 February 2022 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 January 2023 £
Unrestricted funds					
<i>Unrestricted funds</i>					
General Funds - all funds	502,965	873,009	(475,795)	(24,055)	876,124
Restricted					
Restricted Research Funds	21,120	-	-	-	21,120
European Website Project	42,828	16,639	(25,841)	-	33,626
European Conference 2022	59,790	115,000	(198,845)	24,055	-
European Conference 2023	-	35,000	-	-	35,000
Total restricted funds	123,738	166,639	(224,686)	24,055	89,746
Total funds	626,703	1,039,648	(700,481)	-	965,870

The specific purposes for which the funds are to be applied are as follows:

Restricted research funds represent donations where the donor has requested that their donation be used for research purposes only. These donations are held within restricted funds until used in part or in whole to fund a cholangiocarcinoma research project which the charity has committed to supporting.

Restricted funds for the European website project represent donations or sponsorships where the donor has requested that their donation be used for this project only. These donations are held within restricted funds until used in part or in whole to fund the completion of the European website project.

Restricted funds for the European conference 2023 represent donations or sponsorships where the donor has requested that their donation be used for this conference only. These donations are held within restricted funds until used in part or in whole to fund the European conference 2023.

Restricted funds for the External Projects represent sponsorships to support, individual, specific projects AMMF has undertaken. The number of projects vary year from year.

18 Analysis of net assets between funds

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2024

	Unrestricted funds £	Restricted funds £	Total funds at 31 January 2024 £
Tangible fixed assets	4,219	-	4,219
Current assets	1,114,342	80,596	1,194,938
Current liabilities	<u>(182,729)</u>	<u>-</u>	<u>(182,729)</u>
Total net assets	<u><u>935,832</u></u>	<u><u>80,596</u></u>	<u><u>1,016,428</u></u>
			Total funds at 31 January 2023 £
	Unrestricted funds £	Restricted funds £	
Tangible fixed assets	6,615	-	6,615
Current assets	928,897	89,746	1,018,643
Current liabilities	<u>(59,388)</u>	<u>-</u>	<u>(59,388)</u>
Total net assets	<u><u>876,124</u></u>	<u><u>89,746</u></u>	<u><u>965,870</u></u>

19 Related party transactions

There were no related party transactions in the year.

AMMF - THE CHOLANGIOMYOCARCINOMA CHARITY

England & Wales - Charity number 1198095

Accounts

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2023

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 9
Trustees' Responsibilities Statement	10
Independent Examiner's Report	11 - 13
Statement of Financial Activities	14
Balance Sheet	15 - 16
Notes to the Financial Statements	17 - 29

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 JANUARY 2023

Trustees	N Corrigan, Chair G C Corrigan T P Morement H Corrigan
Company registered number	CE028473
Charity registered number	1198095
Registered office	Enterprise House Bassingbourn Road Stansted Essex CM24 1QW
Accountants	Haslers Chartered Accountants Old Station Road Loughton Essex IG10 4PL

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 JANUARY 2023

The trustees present their report with the financial statements of the charity for the year ended 31 January 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

AMMF – The Cholangiocarcinoma Charity was registered with the Charity Commission as a Charitable Incorporated Organisation (CIO) during the year 2022. The CIO registered number with the Charity Commission is 1198095.

The charity was originally registered in 2002 under the name, The Alan Morement Memorial Fund (working title, AMMF) and was an unincorporated charity with the registration number 1091915.

However, because of the continuing growth of the charity, AMMF's trustees decided that it should transition as a legal entity from unincorporated registered charity status to that of a Charitable Incorporated Organisation (CIO). This involved lengthy work with the Charity Commission, and the new CIO status was approved on 01 June, 2022. At that point the work and all assets of the original charity passed to the new CIO charity.

The original charity and its registered number 1091915 will always remain in existence, with all records submitted to the Charity Commission still available on the Commission's website, but this entity will now remain in the background.

The new CIO is officially known as: AMMF – The Cholangiocarcinoma Charity, with the registered number: 1198095.

The aims and objectives of AMMF remain unchanged and the charity's work has and will continue seamlessly and without interruption.

The trustees present their report with the financial statements of the charity for the year ended 31 January 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

AMMF – the Cholangiocarcinoma Charity is the only charity in the UK solely dedicated to cholangiocarcinoma (bile duct cancer). AMMF works nationally throughout the UK, as well as in Europe, and collaborates globally.

AMMF is wholly committed to tackling the devastating cancer, cholangiocarcinoma (CCA), on all fronts and, ultimately, to help find a cure, through:

- Support - Providing information to individuals or groups to support a patient or loved one along their journey
- Empowerment – Empowering patients and their loved ones to advocate for themselves, seek better care, new treatment options and second opinions
- Access – Advocating for patients to ensure they have access to the latest treatment options and a minimum standard of care appropriate to them
- Awareness – Raising awareness of cholangiocarcinoma to support earlier diagnosis, fair and equal access to treatments, including new treatment approaches

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

- Research – Encouraging and supporting continued research into causes, diagnostics, and new treatment options for those with cholangiocarcinoma
- Policy – Ensuring health care policies reflect the needs of those with cholangiocarcinoma

Cholangiocarcinoma is under-represented and under-funded across all areas, including policy, services, and research. It is a poorly understood and under researched disease which is increasing in incidence not only in the UK but throughout the world. Lack of awareness and the difficulties of achieving clear and accurate diagnosis, mean that most are at an advanced stage and inoperable at time of diagnosis.

Surgery remains the only potentially curative treatment - there is palliative chemotherapy and there are a growing number of clinical trials, in particular investigating targeted therapies and immunotherapy - but a diagnosis of inoperable cholangiocarcinoma remains invariably fatal, and this is a situation that has not changed in decades. AMMF is committed to working to change this scenario and strongly believes international collaboration is the way forward.

Resolute in bringing about improvement for the cholangiocarcinoma patient, AMMF continues to work closely with patients and their carers, clinicians, healthcare professionals, researchers, and policy makers, as well as actively collaborating globally.

During the year 2022, the charity continued its advocacy work, especially in helping those with cholangiocarcinoma to navigate their way to continue essential treatments wherever possible.

AMMF's MISSION

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

AMMF's VISION

A world where people can live their lives free of cholangiocarcinoma (CCA) as a life-threatening disease.

Raising Awareness

Cholangiocarcinoma Data Analysis Project

Lack of robust data for cholangiocarcinoma has long been seen by AMMF as a major reason why there is so little awareness of this cancer, and so little progress. Robust data are essential to drive policy, to encourage research funding, to stimulate interest, and so much more.

Working towards rectifying this, Helen Morement, CEO of AMMF, along with Professor Shahid Khan, a hepatologist, and Professor Mireille Toledano, an epidemiologist, both of Imperial College London, prepared a cholangiocarcinoma data project proposal which was submitted to and accepted by the National Cancer Registration and Analysis Service (NCRAS) and Public Health England (PHE) and, in 2019, AMMF entered into a partnership with NCRAS and PHE, employed a data analyst specifically for this work, and the project began

After PHE completed the first part of the project, rather than directly employ another analyst, during the latter part of 2020 AMMF placed the work with the agency Health Data Insight (HDI), who worked closely with PHE on AMMF's behalf. The work continued throughout 2021 and 2022.

Dr Sophie Jose, Senior Analyst at HDI, presented the data project findings to that point at AMMF's conference in May 2022. Key points were:

- Rates of CCA are continuing to increase year on year.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

- Survival continues to be very poor (median survival still only 4 months).
- Over 50% of those receiving a CCA diagnosis in England receive no cancer specific treatment
- There is marked regional variation in incidence and mortality around the country, which has persisted and even worsened over time.
- Overall survival seems to be significantly lower in the most deprived.
- The most common route to diagnosis for cholangiocarcinoma remains the emergency route, which emphasises the poor rate of early diagnosis and the late presentation of this disease.

The CCA data project work completed late in 2022 and then, with AMMF, the PHE and HDI teams began the preparation of three manuscripts for publication during 2023:

- Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 – 2017
- Cholangiocarcinoma across England: a national study of temporal changes in incidence, survival and routes to diagnosis by region and socioeconomic deprivation.
- Cohort study to assess geographical variation in cholangiocarcinoma treatment in England.

AMMF's Hybrid Cholangiocarcinoma Conference 2022

The 2022 conference, held 11-13 May, marked 20 years since the inception of AMMF, and brought together an expert faculty of speakers who reflected over those two decades to measure the progress made, and looked to the future and the work that is still to be done.

Although in the UK, the relaxation of the rules and limitations of surrounding the COVID-19 pandemic made live events possible again, many were still not travelling internationally. So the decision was made to hold AMMF's annual cholangiocarcinoma conference as a hybrid event – face to face at the Radisson Blu Hotel, Stansted, with care taken to ensure the event would be as COVID-safe as possible, but also with the option for those still under travel limitations, or through choice, to attend virtually as the event would be simultaneously streamed across the world.

AMMF was delighted to welcome two internationally renowned specialists at the forefront of the CCA world, Professor Juan Valle (UK) and Professor Jesus Bañales (Spain), to co-chair the anniversary event. They expertly hosted speakers from across the globe who explored UK, European and international aspects of CCA, and enabled the delivery of an inspirational event.

The conference was open to all with an interest in CCA, including specialists, scientists, researchers, clinical nurse specialists, members of the pharmaceutical industry, medical students, patients and carers. More than 600 delegates, including 130 attendees at the Radisson Blu, from six continents registered and over the three days 37 presentations were delivered, plus 14 interactive Q&A sessions. Throughout each day, health care professionals were able to visit a virtual poster hall to see and hear 15 poster presentations, and also to visit the virtual exhibition hall to meet AMMF's sponsors, supporters and representatives of fellow CCA societies from around the world.

As well as presenters from across the UK and Europe who gave updates on treatments and clinical trials, there were presentations giving international insights from China and Southeast Asia.

Scientific updates were delivered by researchers from several of the projects funded by AMMF and these, as

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

well as the scientific updates on experimental modelling and the future of AI, shone a light on the efforts that are being made to understand the complexity of CCA and to develop new diagnostic tools and therapies which will hopefully lead to improved patient outcomes. There were also a number of presentations specifically highlighting the growing number of UK institutions who are now focusing on cholangiocarcinoma.

All the 2022 conference sessions were recorded and remain available to view via AMMF's website. <https://ammf.org.uk/ammf-conference-2022/>

AMMF's European Language Website

AMMF is committed to supporting those with cholangiocarcinoma and, living in a multicultural, multilingual society, it was decided to provide translations of generic sections of AMMF's existing, main website to give as many as possible of those with CCA the support they need and deserve through greater access to the information and resources AMMF provides.

Developed throughout 2021, AMMF's European language website site was formally launched on World Cholangiocarcinoma Day, 12 February 2022. This website is available in 8 European languages – Spanish, French, German, Italian, Polish, Portuguese, Danish, Finnish. www.ammf-eu.org

AMMF Patient Advisory Roundtables

Two patient advisory roundtables were held during 2022, the first on 25 April, the second, a follow up one, was held on 12 July. These were to discuss clinical trials with patients, and to understand how trials are perceived, and also to better understand the impact a diagnosis of CCA has on patients' lives and where there might be areas of unmet need. Reports of the findings were circulated to patients and to the supporting pharmaceutical company, and discussions are ongoing.

Virtual Lab Tour with University of Edinburgh

Over several years, AMMF has funded areas of CCA research work at the University of Edinburgh. In acknowledgement of that, and as one of February's Cholangiocarcinoma Awareness month events, the team in Edinburgh organised a virtual lab tour and a Q&A session on 09 February 2022, for CCA patients and AMMF supporters. This showcased the scope of the work they have been able to undertake as a result of the funding, and to explain some of the findings. This proved a valuable exercise for all attendees both in the terms of learning much more about the painstaking reality of research, and in seeing how important, appreciated and well used supporters' donations are.

The Global Cholangiocarcinoma Alliance

Building on the foundation of three successful annual World Cholangiocarcinoma Days, a venture which was initially an AMMF-instigated initiative, The Global Cholangiocarcinoma Alliance (GCA) was established at AMMF's international workshop held in London in 2018. This Alliance aims to provide a united voice through international collaboration, to seek further ways to drive awareness and education globally, and to address the current challenges in cholangiocarcinoma.

Since that time, AMMF continued to work with the agency Scientific Education Support (SES), acting as the not-for-profit partner as the work towards formalising a governance structure and the formation of an international steering committee was completed.

The international steering committee provided direction and content recommendations for all aspects and initiatives of the GCA. The work has included the annual World Cholangiocarcinoma Day and the development of a dedicated website, designed to provide the global cholangiocarcinoma community with a platform on which to build links and exchange knowledge in order to raise the global awareness of CCA and improve the education of both healthcare professionals and patients.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

As the 'not for profit' partner for the GCA, and after almost five years of working with the agency Scientific Education Support, it was decided that AMMF should exercise due diligence. A Request for Proposal (RFP) process for the work of the GCA was carried out, and the agency AXON have now taken over the work of the alliance. AMMF remains the not for profit partner.

PUBLIC BENEFIT

In forming the charity's objectives and planning the activities, the trustees have considered the Charity Commission's guidance in respect of public benefit.

ACHIEVEMENT AND PERFORMANCE

AMMF remains committed to supporting research into cholangiocarcinoma and opened its grant funding round again in March 2022, following a period during the pandemic when the charity was closed to new applications.

Over the last year several existing awardees requested no cost extensions because the closure of their laboratories during the pandemic, which had resulted in delays to finalizing research work.

Nine applications were accepted during the 2022 round, and were reviewed by AMMF's Scientific Advisory Board. The following are those that were successful, and have been offered and accepted the grant funding as noted:

- Sapienza University of Rome (Professor Carmine Mancone) AMMF Ref: 2022/211

To fund research into, "The role of THBS1, THBS2 and PEDF in the lymphatic dissemination of the intrahepatic cholangiocarcinoma: identification of downstream signalling" Total request: £35,000. **Award: £35,000 (in two instalments)**

- **University of Copenhagen (Professor Jesper B Andersen) AMMF Ref: 2022/212**

To fund work on, "Tumour phenotypes and sensitivities triggered by IL-6 activation in intrahepatic cholangiocarcinoma" Total request: £45,339. **Award: £45,339.00 (in one instalment)**

- **Imperial College London (Shahid A Khan, Joshua B Edel, Aleksandar Ivanov, Micol Damiani) AMMF Ref:2022/213**

To fund research into, "Single-molecule multiplexed detection of biomarkers for HCC and CCA using a novel nanopore-based sensing". Total request: £27,625.78. **Award: £27,625.78 (in one instalment)**

- **University of Nottingham (Kevin Gaston, Sheela Jayaraman, Isioma Egbuniwe) AMMF Ref: 2022/214**

To fund research into, "Ultra high-resolution mapping of spatial patterns of gene and protein expression in cholangiocarcinoma and the cholangiocarcinoma tumour microenvironment". Total request: £48,500. **Award: £24,250.00**

- University of Nottingham (Sheela Jayaraman, Anna Grabowksa, Kevin Gaston) AMMF Ref: 2022/215

To fund work on combination therapies for cholangiocarcinoma. Total request: £45,158. **Award: £22,000.00**

- **University of Manchester, CR UK (Alicia-Marie Conway, Natalie Cook, Juan Valle, Dominic Rothwell) AMMF Ref: 2022/216**

To fund research into, "Intrahepatic cholangiocarcinoma hidden amongst the unknown: biomarker discovery and

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

novel diagnostic approach from circulation: Free DNA (cfDNA) in cancers of unknown primary". Total request: £110,695.94. **Award: £30,850.00**

During 2022 the following payments were made re new and existing awards:

University of Liverpool - £23,789.84 was requested and paid on 16.02.2022. This single payment represents the full amount re the award (of £25,000) agreed to fund the work of Dr Marc Quinn in the identification of actionable drug targets in perihilar cholangiocarcinoma using a whole exome sequencing approach.

University of Edinburgh. £33,365.00 was paid on 20.05.2022 in respect of the 3rd and final instalment of the award of £102,595 agreed in September 2017 to fund a 3 year PhD scholarship in Dr Luke Boulter's lab, for the project, " Understanding the role of seed cells and epithelial co-option in cholangiocarcinoma."

University of Copenhagen - £45,339.00 was paid 07.12.2022, representing the full amount of the award agreed to fund the work of Professor Jesper Andersen on "Tumour phenotypes and sensitivities triggered by IL-6 activation in intrahepatic cholangiocarcinoma".

Imperial College London - £27,625.78 was paid on 14.12.2022, representing the full amount of the award agreed to fund the work of Professor Shahid Khan's team in the detection of single-molecule multiplexed detection of biomarkers for HCC and CCA using a novel nanopore-based sensing.

University of Leeds – a final payment of **£3,345.09** was made on 09.01.2023 against invoiced actual consumable spend in respect of an award of £45,000 which was agreed in July 2018 to be given over three years, to fund consumables required in the work of Dr Stephen Griffin on virus-driven intrahepatic cholangiocarcinoma.

Donostia University Hospital, Spain - £10,225.00 (3rd and final instalment) was paid in Euros on 09.01.2023 in respect of an award of £32,048.00 agreed in 2019 to be given in 3 instalments to fund Dr Jesus Bafales's work on the role of the transcription factor KLF5 in the etiopathogenesis of cholangiocarcinoma, a new diagnostic, prognostic and therapeutic strategy.

AMMF's External Activities

AMMF is recognized widely, nationally and internationally, amongst both the general public and within medical circles, for its work in the field of cholangiocarcinoma, and is frequently invited to become part of study groups and advisory boards, for example, the working group for Liver Transplantation for Cholangiocarcinoma, and the executive committee of Cholangiocarcinoma-UK.

During the year, AMMF was involved with the new British Society of Gastroenterology (BSG) Guidelines for the Diagnosis and Management of Cholangiocarcinoma. Along with a number of CCA specialists, led by Professor Shahid Khan, who have all written on their specialisms, AMMF's CEO contributed a chapter, "Patient/Public Perspective" which is included in this new work.

AMMF is also a member of the European Network for the Study of Cholangiocarcinoma (ENS-CCA), an association of research groups from across Europe and beyond, actively working on basic, translational, and clinical research into cholangiocarcinoma, and AMMF's CEO is chair of the ENS-CCA Patient Advocacy Committee.

AMMF continues to be an active member of Cancer52, the alliance of rare and less common cancer organisations in the UK. AMMF's CEO, Helen Morement was appointed a board director of Cancer52 in 2014, and has continued in that role since then. She also acted as interim co-chair during the year (with fellow Cancer52 board member, Rebecca Porta, CEO of The Urology Foundation) whilst a new chair of trustees was sought. Through membership of Cancer52, AMMF is enabled to have a presence and a voice within every national cancer initiative and AMMF's trustees see this as providing an important opportunity to work more

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

closely with this increasingly influential organisation, and in identifying priority challenges and opportunities for all those in the rare and less common cancers community.

During the year, AMMF's CEO attended and presented at a number of meetings and conferences, including presenting the work of AMMF at the Scottish Annual Hepatobiliary (HPB) Conference, speaking on the topic of "Hepatobiliary Cancers – from the Patient Advocate's Point of View" at the National Cancer Research Institute (NCRI) Hepatobiliary Study Group's annual meeting, and on "The impact of advocacy in cholangiocarcinoma" at the ENS-CCA Annual Conference, held in Edinburgh.

During 2022, AMMF was invited by the National Institute for Health and Care Excellence (NICE) to submit responses as a patient advocacy organisation, and CEO Helen Morement as a patient expert, for four therapies applicable to cholangiocarcinoma, which had been put forward for approval. Written submissions were made, and the appraisals are scheduled to take place at NICE committee meetings during 2023.

(The therapies are: durvalumab (with gemcitabine and cisplatin) Appraisal 4031; Ivosidenib Appraisal 6164; Pembrolizumab (ID4036); Pembrolizumab with gemcitabine and cisplatin (ID4034))

Providing information for those who need it

AMMF's CEO attended monthly virtual NHS cancer charity briefing meetings throughout 2022. These regular meetings, which began during the pandemic, are now proving informative, hearing about new developments in NHS processes and campaigns in a timely manner. AMMF's Medical and Clinical Advisors are contacted on a regular basis for help and advice on how best to handle the more difficult patient queries the charity receives, and for up to date information on clinical trials.

AMMF's website continued to be updated regularly, and aims to provide information on all aspects of cholangiocarcinoma, including treatments and specialists, the advances being made and, importantly, there is a comprehensive list of the clinical trials that are available and recruiting in the UK, which is proving a valuable resource to medics and patients. www.ammf.org.uk

The charity's active social media platforms kept supporters up to date with information of importance and relevance to them throughout the year. AMMF's Facebook page now has over 5,700 followers, and the following on Twitter, Instagram and LinkedIn continues to grow.

In answer to patients' requests, AMMF opened two private, member only, support groups on Facebook - Cholangiocarcinoma Support – UK and Europe, and a group for those bereaved by cholangiocarcinoma. These have been well received and are actively used on a daily basis, proving an invaluable resource for patients to share information, and for them to help and support each other.

The requirement from individual patients and family members for specific information regarding specialist consultants and treatments continues to increase. With the wider awareness of the charity, increasing incidence and growing recognition of cholangiocarcinoma, it is anticipated this area of work will continue to grow.

In summary

All government restrictions to travel and office-based working were lifted by the early part of 2022, and the board of trustees considered it safe for all AMMF staff to resume working full time at AMMF's Enterprise House offices. However, the COVID situation continued to be monitored on an ongoing basis.

The pandemic caused unforeseen difficulties over the previous two years but, despite the problems, the charity has continued its work steadfastly through the lockdowns, and throughout 2022, expanding its reach and influence nationally and internationally.

As we enter 2023 and the charity's 21st year since its initial inception, AMMF, the UK's only cholangiocarcinoma

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

charity, is now firmly established in the UK, Europe and beyond. Although by its nature it will remain a niche charity, AMMF has grown steadily over the years and, with the continued help of the loyal fundraisers and supporters, we will continue our work and remain fully committed to working towards a far better future for all those diagnosed with cholangiocarcinoma.

Financial review

The charity has continued to strengthen its financial position during the year.

The charity ensures that sufficient reserves are retained in an appropriate form to fund its current obligations.

Where specific research projects have been secured, the trustees designate sufficient unrestricted reserves to cover the expected future grants payable over the term of the research project.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a CIO.

Approved by order of the members of the board of Trustees on 3 November 2023 and signed on their behalf by:



N Corrigan
(Chair of Trustees)

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 JANUARY 2023

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 3 November 2023 and signed on its behalf by:



N Corrigan
(Chair of Trustees)

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 JANUARY 2023

Independent Examiner's Report to the Trustees of AMMF - The Cholangiocarcinoma Charity ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 January 2023.

Responsibilities and Basis of Report

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

Independent Examiner's Statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ACCA, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2023

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:



Dated: 3 November 2023

P Thain

Haslers

Chartered Accountants

Old Station Road

Loughton

Essex

IG10 4PL

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 JANUARY 2023**

	Note	Restricted funds 2023 £	Unrestricted funds 2023 £	Total funds Combined 2023 £	Total funds Unincorporated 2022 £
Income from:					
Donations and legacies	3	166,639	863,852	1,030,491	821,649
Other trading activities	4	-	7,760	7,760	14,055
Investments	5	-	1,397	1,397	646
Total income		166,639	873,009	1,039,648	836,350
Expenditure on:					
Raising funds		-	4,115	4,115	2,276
Charitable activities	6	224,686	471,680	696,366	627,575
Total expenditure		224,686	475,795	700,481	629,851
Net (expenditure)/income		(58,047)	397,214	339,167	206,499
Transfers between funds	14	24,055	(24,055)	-	-
Net movement in funds		(33,992)	373,159	339,167	206,499
Reconciliation of funds:					
Total funds brought forward		123,738	502,965	626,703	420,204
Net movement in funds		(33,992)	373,159	339,167	206,499
Total funds carried forward		89,746	876,124	965,870	626,703

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 17 to 29 form part of these financial statements.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)
REGISTERED NUMBER: CE028473

BALANCE SHEET
AS AT 31 JANUARY 2023

	Note	Combined 2023 £	<i>Unincorporated</i> 2022 £
Fixed assets			
Tangible assets	10	6,615	-
		<u>6,615</u>	<u>-</u>
Current assets			
Stocks	11	7,386	7,122
Debtors	12	40,211	12,144
Cash at bank and in hand		971,046	733,883
		<u>1,018,643</u>	<u>753,149</u>
Creditors: amounts falling due within one year	13	(59,388)	(126,446)
Net current assets		<u>959,255</u>	<u>626,703</u>
Total assets less current liabilities		<u>965,870</u>	<u>626,703</u>
Total net assets		<u><u>965,870</u></u>	<u><u>626,703</u></u>
Charity funds			
Restricted funds	14	89,746	123,738
Unrestricted funds	14	876,124	502,965
Total funds		<u><u>965,870</u></u>	<u><u>626,703</u></u>

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)
REGISTERED NUMBER: CE028473

BALANCE SHEET (CONTINUED)
AS AT 31 JANUARY 2023

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on 03 November 2023 and signed on their behalf by:



N Corrigan
(Chair of Trustees)

The notes on pages 17 to 29 form part of these financial statements.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

1. General information

AMMF - The Cholangiocarcinoma Charity is a charitable incorporated organisation, domiciled in England and Wales, registration number CE028473, charity number 1198095. The registered office is Enterprise House, Bassingbourn Road, Stansted, Essex, CM24 1QW and the principal place of business is throughout the United Kingdom. The principal aim of the charity is to raise awareness of cholangiocarcinoma (bile duct cancer), supply information to those who need it, and to raise funds to support specialised research teams in their work into the causes, methods of earlier diagnosis and treatments of this disease.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

AMMF - The Cholangiocarcinoma Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

2. Accounting policies (continued)

2.4 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.5 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment	-	33%
--------------------	---	-----

2.6 Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

2.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.8 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.9 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of Financial Activities as a finance cost.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

2. Accounting policies (continued)

2.10 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	Restricted funds Combined 2023 £	Unrestricted funds Combined 2023 £	Total funds Combined 2023 £	<i>Total funds Unincorporated 2022 £</i>
Donations	166,639	863,852	1,030,491	821,649
<i>Total 2022</i>	<u>140,618</u>	<u>681,031</u>	<u>821,649</u>	

4. Income from other trading activities

Income from non charitable trading activities

	Unrestricted funds Combined 2023 £	Total funds Combined 2023 £	<i>Total funds Unincorporated 2022 £</i>
Shop income	7,760	7,760	14,055
	<u>7,760</u>	<u>7,760</u>	<u>14,055</u>

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

5. Investment income

	Unrestricted funds Combined 2023 £	Total funds Combined 2023 £	<i>Total funds Unincorporated 2022 £</i>
Deposit account interest	1,397	1,397	646
<i>Total 2022</i>	<u>646</u>	<u>646</u>	

6. Analysis of expenditure on charitable activities

Summary by fund type

	Restricted funds Combined 2023 £	Unrestricted funds Combined 2023 £	Total Combined 2023 £	<i>Total Unincorporated 2022 £</i>
Costs	224,686	471,680	696,366	627,575
<i>Total 2022</i>	<u>38,000</u>	<u>589,575</u>	<u>627,575</u>	

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

7. Analysis of expenditure by activities

	Activities undertaken directly Combined 2023 £	Support costs Combined 2023 £	Total funds Combined 2023 £	<i>Total funds Unincorporated 2022 £</i>
Costs	364,967	331,399	696,366	627,575
<i>Total 2022</i>	<u>232,087</u>	<u>395,488</u>	<u>627,575</u>	

Analysis of direct costs

	Total funds Combined 2023 £	<i>Total funds Unincorporated 2022 £</i>
Grants to institutions	155,492	194,087
European Website costs	25,841	37,790
European Conference costs	161,557	210
Workshop costs	22,077	-
	<u>364,967</u>	<u>232,087</u>

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

7. Analysis of expenditure by activities (continued)

Analysis of support costs

	Total funds Combined 2023 £	<i>Total funds Unincorporated 2022 £</i>
Staff costs	82,158	71,234
Depreciation	948	858
Equipment leasing	-	2,982
Operating lease - office rent & service charges	31,195	29,064
Rates and water	1,638	1,638
Insurance	256	1,068
Marketing and advertising	122,433	115,238
Telephone	5,562	2,708
Postage and stationery	3,616	2,005
Computer and website support	13,944	21,402
Travel	4,050	1,099
Subscriptions	1,595	1,449
Sundries	5	760
Training	215	15
Legal and Professional fees	49,931	106,064
Conference expenses	13,200	37,288
Bank charges	653	616
	331,399	395,488

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

8. Staff costs

	Combined 2023 £	<i>Unincorporated 2022 £</i>
Wages and salaries	78,173	67,958
Social security costs	3,060	2,398
Contribution to defined contribution pension schemes	924	877
	82,157	71,233

The average number of persons employed by the Charity during the year was as follows:

	Combined 2023 No.	<i>Unincorporated 2022 No.</i>
Employees	3	3

No employee received remuneration amounting to more than £60,000 in either year.

9. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the year ended 31 January 2023, no Trustee expenses have been incurred (2022 - £NIL).

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

10. Tangible fixed assets

	Computer equipment £
Cost or valuation	
At 1 February 2022 Unincorporated	10,305
Additions	7,564
Disposals	(4,291)
	13,578
At 31 January 2023	13,578
Depreciation	
At 1 February 2022 Unincorporated	10,305
Charge for the year	948
On disposals	(4,291)
	6,962
At 31 January 2023	6,962
Net book value	
At 31 January 2023	6,616
<i>At 31 January 2022</i> Unincorporated	-

11. Stocks

	2023	<i>Unincorporated</i> 2022
	£	£
Finished goods and goods for resale	7,386	7,122

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

12. Debtors

	2023	<i>Unincorporated</i>
	£	2022
		£
Due within one year		
Trade debtors	2,190	-
Other debtors	1,228	1,228
Prepayments and accrued income	36,793	10,916
	40,211	12,144

13. Creditors: Amounts falling due within one year

	2023	<i>Unincorporated</i>
	£	2022
		£
Trade creditors	48,530	123,276
Other creditors	5,458	1,370
Accruals and deferred income	5,400	1,800
	59,388	126,446

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

14. Statement of funds

Statement of funds - current year

	Unincorporated Balance at 1 February 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 January 2023 £
Unrestricted funds					
General Funds - all funds	502,965	873,009	(475,795)	(24,055)	876,124
Restricted funds					
Restricted Research Funds	21,120	-	-	-	21,120
European Website Project	42,828	16,639	(25,841)	-	33,626
European Conference 2022	59,790	115,000	(198,845)	24,055	-
European Conference 2023	-	35,000	-	-	35,000
	<u>123,738</u>	<u>166,639</u>	<u>(224,686)</u>	<u>24,055</u>	<u>89,746</u>
Total of funds	<u><u>626,703</u></u>	<u><u>1,039,648</u></u>	<u><u>(700,481)</u></u>	<u><u>-</u></u>	<u><u>965,870</u></u>

Restricted research funds represent donations where the donor has requested that their donation be used for research purposes only. These donations are held within restricted funds until used in part or in whole to fund a cholangiocarcinoma research project which the charity has committed to supporting.

Restricted funds for the European website project represent donations where the donor has requested that their donation be used for this project only. These donations are held within restricted funds until used in part or in whole to fund the completion of the European website project.

Restricted funds for the European conference 2022 represent donations where the donor has requested that their donation be used for this conference only. These donations are held within restricted funds until used in part or in whole to fund the European conference 2022.

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

14. Statement of funds (continued)

Statement of funds - prior year

	<i>Unincorporated Balance at 1 February 2021 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Unincorporated Balance at 31 January 2022 £</i>
Unrestricted funds				
General Funds - all funds	399,084	695,732	(591,851)	502,965
	<u>399,084</u>	<u>695,732</u>	<u>(591,851)</u>	<u>502,965</u>
	<i>Unincorporated Balance at 1 February 2021 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Unincorporated Balance at 31 January 2022 £</i>
Restricted funds				
Restricted Research Funds	21,120	-	-	21,120
European Website Project	-	80,618	(37,790)	42,828
European Conference 2022	-	60,000	(210)	59,790
	<u>21,120</u>	<u>140,618</u>	<u>(38,000)</u>	<u>123,738</u>
	<u>21,120</u>	<u>140,618</u>	<u>(38,000)</u>	<u>123,738</u>
Total of funds	<u>420,204</u>	<u>836,350</u>	<u>(629,851)</u>	<u>626,703</u>

15. Summary of funds

Summary of funds - current year

	Unincorporated Balance at 1 February 2022 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 January 2023 £
General funds	502,965	873,009	(475,795)	(24,055)	876,124
Restricted funds	123,738	166,639	(224,686)	24,055	89,746
	<u>626,703</u>	<u>1,039,648</u>	<u>(700,481)</u>	<u>-</u>	<u>965,870</u>
	<u>626,703</u>	<u>1,039,648</u>	<u>(700,481)</u>	<u>-</u>	<u>965,870</u>

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

15. Summary of funds (continued)

Summary of funds - prior year

	<i>Balance at 1 February 2021</i>	<i>Income</i>	<i>Expenditure</i>	<i>Balance at 31 January 2022</i>
	£	£	£	£
General funds	399,084	695,732	(591,851)	502,965
Restricted funds	21,120	140,618	(38,000)	123,738
	<u>420,204</u>	<u>836,350</u>	<u>(629,851)</u>	<u>626,703</u>

16. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Restricted funds 2023	Unrestricted funds 2023	Total funds 2023
	£	£	£
Tangible fixed assets	-	6,615	6,615
Current assets	89,746	928,897	1,018,643
Creditors due within one year	-	(59,388)	(59,388)
Total	<u>89,746</u>	<u>876,124</u>	<u>965,870</u>

Analysis of net assets between funds - prior year

	<i>Restricted funds 2022</i>	<i>Unrestricted funds 2022</i>	<i>Total funds 2022</i>
	£	£	£
Current assets	123,738	629,411	753,149
Creditors due within one year	-	(126,446)	(126,446)
Total	<u>123,738</u>	<u>502,965</u>	<u>626,703</u>

AMMF - THE CHOLANGIOCARCINOMA CHARITY
(A Charitable Incorporated Organisation)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

17. Related party transactions

The AMMF - The Cholangiocarcinoma Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the AMMF - The Cholangiocarcinoma Charity at 31 January 2023.

18. Charity merger

This Charity was incorporated on 1st March 2022 for the purpose of continuing the existing charity work of The Alan Morement Memorial Fund registered charity number 1091915 including its purpose and beneficiary class that will remain unchanged.

At midnight on 31st May 2022 The Alan Morement Memorial Fund transferred its charitable undertaking to AMMF - The Cholangiocarcinoma Charity by way of a £746,271 donation as per a transfer agreement written up between the two entities.

As this Charity was set up as the corporate successor of The Alan Morement Memorial Fund we are showing the unincorporated charities figures as prior years comparatives and the current years figures are made up of both the unincorporated and corporated charities combined movements for the year.